Communiqués Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
70,65 ^USD	-1,12 %		-3,80 %	-13,72 %

12/08	Tarsus Pharmaceuticals, Inc. : Oppenheimer optimiste sur le dossier	ZM
07/08	Tarsus Pharmaceuticals, Inc. : Mizuho Securities toujours à l'achat	ZM

Communiqués

06/08	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing	GL
06/08	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position	GL
06/08	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth	GL
06/08	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026	GL
13/07	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth	GL
08/07	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101	GL
28/05	Tarsus to Participate in Upcoming Investor Conferences	GL
14/05	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans	GL
07/05	Tarsus to Participate in Upcoming Investor Conferences	GL
07/05	Tarsus Pharmaceuticals : Reports First Quarter 2026 Financial Results and Recent Business Achievements	PU
07/05	Tarsus Pharmaceuticals : First Quarter 2026 Earnings Presentation	PU
06/05	Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements	GL
29/04	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026	GL
01/04	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05, a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease	AQ
31/03	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease	GL
23/03	TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus	GL
26/02	Tarsus to Participate in Upcoming Investor Conferences	GL
24/02	Tarsus Pharmaceuticals : Fourth Quarter and Full Year 2025 Earnings Presentation	PU
23/02	Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements	GL
18/02	Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors	GL
17/02	Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026	GL
24/11	Tarsus to Participate in Upcoming Investor Conference	GL
05/11	Tarsus to Participate in Upcoming Investor Conference	GL
04/11	Tarsus Pharmaceuticals : Third Quarter 2025 Earnings Presentation	PU
04/11	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements	GL